Home

Welcome to NLS Pharma

We design affordable, safe and effective drugs to safeguard and empower the brain throughout all stages of life. Our aim is to improve quality of life and longevity. We are creating new approaches to treat mental and behavioral disorders, and to enhance cognitive function in healthy people.

Founders

Our multidisciplinary Team, led by professionals with a long track record in drug development and management, relies on highly skilled personnel with unique competence in developing integrated solutions.

Latest News

  • Oct 31, 2017
    NLS Pharma Announces Poster Presentation On Efficacy and Safety Data of a Controlled Release (CR) Formulation of Mazindol in Adults with ADHD at AACAP’s & APSARD’s Annual Meeting
  • May 31, 2017
    NLS Pharma unveils positive phase 2 data for NLS-1 (Mazindol CR) in adults with ADHD, demonstrating significant improvement in symptoms
  • May 26, 2017
    NLS Pharma announces new information in support of the mechanism of action of its lead compound NLS-1 Mazindol CR
  • May 16, 2017
    NLS Pharma announces phase 2 study of NLS-1 (MAZINDOL) in adult ADHD patients has met all primary and secondary endpoints
Contact us

NLS Pharma is very interested in hearing from you. Please find general contact information below.

NLS PHARMA GROUP
Alter Postplatz 2
CH-6370 Stans NW
Switzerland

T: +41 41 618 80 00
F: +41 41 618 80 09
askus@nls-pharma.com

Your Name (required)

Your Email (required)

Subject

Your Message